A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2019

ABSTRACT

This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann-Pick disease Type C1 (NPC-1) is safe at 3 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in a protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 56 weeks in total. recruitment is expected to take 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. Samples of Cerebrospinal fluid (CSF) are also taken by lumbar puncture during and following the first treatment dose. Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment. Optional assessments patients can choose to take part in include liver biopsies, additional lumbar punctures for CSF.examinations to see if the drug is affecting these. This study is being sponsored and funded by CTD holdings INC. It is planned to be run in the UK, Italy, and Sweden. Detailed Description The planned study has been designed as a Phase I/II, double-blind, randomised, multi-centre, parallel group study based on information and data available from the administration of Trappsol Cyclo via compassionate/named patient use in patients with NPC-1, and data on other cyclodextrin products in the scientific literature. The study is comprised of two stages. The primary objective of Stage 1 is to compare the plasma pharmacokinetics of three different doses of IV Trappsol Cyclo in the prevention /delay of NPC-1 progression.Secondary objectives include investigation of the Hydroxypropyl Beta Cyclodextrin (HP-β-CD) effect of three different doses of IV Trappsol Cyclo upon serum and lymphocytic markers of cholesterol metabolism (Stages 1 and 2) and evaluation of concentrations in the cerebrospinal fluid (CSF) following intravenous (IV) administration (Stage 1), evaluation of the impact of treatment upon measures of neurological function including ataxia, aphasia and saccadic eye movements, and the impact of treatment upon behavioural aspects of NPC-1 (Stage 2). It is planned to recruit a total of 12 patients to the study. Patients will be randomised 1:1:1 to one of the three dose levels (1500 mg/kg, 2000 mg/kg or 2500 mg/kg; four patients per dose level). Treatment will be administered every two weeks by slow IV infusion at a concentration of 250 mg/mL over 8 hours. Patients completing Stage 1 of the study will continue into Stage 2 and receive treatment for 48 weeks. Patients who withdraw prior to completion of the initial pharmacokinetic (PK) and pharmacodynamics (PD) assessments will be replaced. The design of the proposed study thus enables early assessment of biochemical markers of response but allows for a sufficient dosing duration to enable the effectiveness of Trappsol in NPC-1 to be assessed. As miglustat is an approved treatment for NPC-1 in the EU, with an established efficacy and safety profile, it would be unethical to exclude patients receiving miglustat therapy from the study, given that the study itself will also be conducted at sites in Europe. However, it is planned to balance randomisation across the treatment groups for its use. The maximum dose proposed for this study is below the maximum dose for which long term clinical data is available in 2 patients (2800 mg/kg weekly for 3-5 years). Although individual clinicians have not always utilised an escalating rate of infusion, the reports of infusion related reactions in three patients suggest that this is an appropriate clinical strategy to mitigate the risk of such events and is consistent with dosing administration for other therapeutic agents. In the proposed study, treatment will be administered less frequently than has been undertaken in compassionate use. This longer dosing interval is supported by nonclinical data comparing the metabolism of cholesterol in non-human species with that in man; although a once weekly dosing interval was initially studied in man based on data in the mouse, HP-β-CD cholesterol metabolism/turnover in the mouse is 13-fold higher than in man which, in NPC-1, likely translates into a 13-fold slower accumulation of cholesterol in human cells compared with those of the mouse.Therefore, it is theorised that, given the slower cholesterol metabolism in humans, the dosing interval could be much less frequent in man than in mouse; however, based on what is known about cholesterol metabolism in humans and the pharmacokinetic and pharmacodynamic effect of HP-β-CD in the mouse, a dosing interval of 2 weeks in man is likely to be well within the therapeutic dosing interval and also minimises the amount of infusions required to be administered. More... »

URL

https://clinicaltrials.gov/show/NCT02912793

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3164", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This research study is being conducted to find out whether Trappsol\u00ae Cyclo\u2122, an experimental treatment for people with Niemann-Pick disease Type C1 (NPC-1) is safe at 3 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in a protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 56 weeks in total. recruitment is expected to take 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. Samples of Cerebrospinal fluid (CSF) are also taken by lumbar puncture during and following the first treatment dose. Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment. Optional assessments patients can choose to take part in include liver biopsies, additional lumbar punctures for CSF.examinations to see if the drug is affecting these. This study is being sponsored and funded by CTD holdings INC. It is planned to be run in the UK, Italy, and Sweden.\n\nDetailed Description\nThe planned study has been designed as a Phase I/II, double-blind, randomised, multi-centre, parallel group study based on information and data available from the administration of Trappsol Cyclo via compassionate/named patient use in patients with NPC-1, and data on other cyclodextrin products in the scientific literature. The study is comprised of two stages. The primary objective of Stage 1 is to compare the plasma pharmacokinetics of three different doses of IV Trappsol Cyclo in the prevention /delay of NPC-1 progression.Secondary objectives include investigation of the Hydroxypropyl Beta Cyclodextrin (HP-\u03b2-CD) effect of three different doses of IV Trappsol Cyclo upon serum and lymphocytic markers of cholesterol metabolism (Stages 1 and 2) and evaluation of concentrations in the cerebrospinal fluid (CSF) following intravenous (IV) administration (Stage 1), evaluation of the impact of treatment upon measures of neurological function including ataxia, aphasia and saccadic eye movements, and the impact of treatment upon behavioural aspects of NPC-1 (Stage 2). It is planned to recruit a total of 12 patients to the study. Patients will be randomised 1:1:1 to one of the three dose levels (1500 mg/kg, 2000 mg/kg or 2500 mg/kg; four patients per dose level). Treatment will be administered every two weeks by slow IV infusion at a concentration of 250 mg/mL over 8 hours. Patients completing Stage 1 of the study will continue into Stage 2 and receive treatment for 48 weeks. Patients who withdraw prior to completion of the initial pharmacokinetic (PK) and pharmacodynamics (PD) assessments will be replaced. The design of the proposed study thus enables early assessment of biochemical markers of response but allows for a sufficient dosing duration to enable the effectiveness of Trappsol in NPC-1 to be assessed. As miglustat is an approved treatment for NPC-1 in the EU, with an established efficacy and safety profile, it would be unethical to exclude patients receiving miglustat therapy from the study, given that the study itself will also be conducted at sites in Europe. However, it is planned to balance randomisation across the treatment groups for its use. The maximum dose proposed for this study is below the maximum dose for which long term clinical data is available in 2 patients (2800 mg/kg weekly for 3-5 years). Although individual clinicians have not always utilised an escalating rate of infusion, the reports of infusion related reactions in three patients suggest that this is an appropriate clinical strategy to mitigate the risk of such events and is consistent with dosing administration for other therapeutic agents. In the proposed study, treatment will be administered less frequently than has been undertaken in compassionate use. This longer dosing interval is supported by nonclinical data comparing the metabolism of cholesterol in non-human species with that in man; although a once weekly dosing interval was initially studied in man based on data in the mouse, HP-\u03b2-CD cholesterol metabolism/turnover in the mouse is 13-fold higher than in man which, in NPC-1, likely translates into a 13-fold slower accumulation of cholesterol in human cells compared with those of the mouse.Therefore, it is theorised that, given the slower cholesterol metabolism in humans, the dosing interval could be much less frequent in man than in mouse; however, based on what is known about cholesterol metabolism in humans and the pharmacokinetic and pharmacodynamic effect of HP-\u03b2-CD in the mouse, a dosing interval of 2 weeks in man is likely to be well within the therapeutic dosing interval and also minimises the amount of infusions required to be administered.", 
    "endDate": "2019-08-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02912793", 
    "keywords": [
      "phase I/II study", 
      "Evaluate", 
      "safety", 
      "cyclo", 
      "HP", 
      "Niemann-Pick disease", 
      "NPC", 
      "pharmacodynamic effect", 
      "cholesterol metabolism", 
      "clinical outcome", 
      "research study", 
      "experimental treatment", 
      "C1", 
      "different dose level", 
      "condition", 
      "defect", 
      "protein", 
      "transport", 
      "substance", 
      "cholesterol", 
      "cell", 
      "organ damage", 
      "laboratory experiment", 
      "patient", 
      "recruitment", 
      "intravenous infusion", 
      "body", 
      "drug", 
      "blood", 
      "urine sample", 
      "sample", 
      "cerebrospinal fluid", 
      "Spinal Puncture", 
      "first treatment", 
      "hearing", 
      "doctor", 
      "questionnaire", 
      "assessment", 
      "liver biopsy", 
      "puncture", 
      "holding", 
      "UK", 
      "Italy", 
      "Sweden", 
      "planned study", 
      "Phase I/II", 
      "multi-centre", 
      "parallel group study", 
      "Organization and Administration", 
      "patient use", 
      "cyclodextrins", 
      "scientific literature", 
      "stage", 
      "primary objective", 
      "Stage 1", 
      "plasma pharmacokinetics", 
      "different dose", 
      "prevention", 
      "secondary objective", 
      "beta-cyclodextrin", 
      "serum", 
      "marker", 
      "Evaluation Study as Topic", 
      "Attention", 
      "neurological function", 
      "ataxia", 
      "aphasia", 
      "saccade", 
      "behavioral aspect", 
      "Stage 2", 
      "dose level", 
      "infusion", 
      "Completing", 
      "pharmacodynamics", 
      "PD", 
      "early assessment", 
      "Biological Marker", 
      "duration", 
      "effectiveness", 
      "approved treatment", 
      "established efficacy", 
      "safety profile", 
      "therapy", 
      "Europe", 
      "randomisation", 
      "treatment group", 
      "maximum dose", 
      "clinical data", 
      "individual", 
      "escalating", 
      "related reaction", 
      "clinical strategy", 
      "risk", 
      "dosing", 
      "therapeutic agent", 
      "trial", 
      "interval", 
      "metabolism", 
      "non-human specie", 
      "human", 
      "mouse", 
      "translates", 
      "accumulation", 
      "human cell", 
      "therapeutic", 
      "minimise"
    ], 
    "name": "A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-\u03b2-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02912793"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00022.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.83440.3b", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412346.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.415721.4", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-03-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1179/jmt.2009.17.3.163", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002816074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1750-1172-5-16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005623887", 
          "https://doi.org/10.1186/1750-1172-5-16"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-015-0274-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005979361", 
          "https://doi.org/10.1186/s13023-015-0274-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/humu.10255", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006616197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.10541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006635563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1194/jlr.m700525-jlr200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012167280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.271.35.21604", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012367026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3010101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012551405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1194/jlr.m013789", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014481242"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1242/dmm.010124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019513430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(07)70194-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021955671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci72835", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023308017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.b.30969", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026935211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ymgme.2012.03.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027225530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-3956(75)90026-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027523106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/8904_2011_47", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035654877", 
          "https://doi.org/10.1007/8904_2011_47"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0114669", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037474842"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jnnp.2005.086785", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037485737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0810895106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039042817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/aud.0b013e3182a362b8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044245566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004399900059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047616516", 
          "https://doi.org/10.1007/s004399900059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004399900059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047616516", 
          "https://doi.org/10.1007/s004399900059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.282.12.1157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050564301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.fct.2005.03.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052037868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/brain/awl260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052588466"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.21544", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053003540"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/302620", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058610189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.290.5500.2298", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062572556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000219042.60538.92", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064348165"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e31828869f9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064357619"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02912793"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02912793'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02912793'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02912793'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02912793'


 

This table displays all metadata directly associated to this object as RDF triples.

223 TRIPLES      16 PREDICATES      153 URIs      115 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02912793 schema:about anzsrc-for:3053
2 anzsrc-for:3164
3 schema:description This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann-Pick disease Type C1 (NPC-1) is safe at 3 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in a protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 56 weeks in total. recruitment is expected to take 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. Samples of Cerebrospinal fluid (CSF) are also taken by lumbar puncture during and following the first treatment dose. Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment. Optional assessments patients can choose to take part in include liver biopsies, additional lumbar punctures for CSF.examinations to see if the drug is affecting these. This study is being sponsored and funded by CTD holdings INC. It is planned to be run in the UK, Italy, and Sweden. Detailed Description The planned study has been designed as a Phase I/II, double-blind, randomised, multi-centre, parallel group study based on information and data available from the administration of Trappsol Cyclo via compassionate/named patient use in patients with NPC-1, and data on other cyclodextrin products in the scientific literature. The study is comprised of two stages. The primary objective of Stage 1 is to compare the plasma pharmacokinetics of three different doses of IV Trappsol Cyclo in the prevention /delay of NPC-1 progression.Secondary objectives include investigation of the Hydroxypropyl Beta Cyclodextrin (HP-β-CD) effect of three different doses of IV Trappsol Cyclo upon serum and lymphocytic markers of cholesterol metabolism (Stages 1 and 2) and evaluation of concentrations in the cerebrospinal fluid (CSF) following intravenous (IV) administration (Stage 1), evaluation of the impact of treatment upon measures of neurological function including ataxia, aphasia and saccadic eye movements, and the impact of treatment upon behavioural aspects of NPC-1 (Stage 2). It is planned to recruit a total of 12 patients to the study. Patients will be randomised 1:1:1 to one of the three dose levels (1500 mg/kg, 2000 mg/kg or 2500 mg/kg; four patients per dose level). Treatment will be administered every two weeks by slow IV infusion at a concentration of 250 mg/mL over 8 hours. Patients completing Stage 1 of the study will continue into Stage 2 and receive treatment for 48 weeks. Patients who withdraw prior to completion of the initial pharmacokinetic (PK) and pharmacodynamics (PD) assessments will be replaced. The design of the proposed study thus enables early assessment of biochemical markers of response but allows for a sufficient dosing duration to enable the effectiveness of Trappsol in NPC-1 to be assessed. As miglustat is an approved treatment for NPC-1 in the EU, with an established efficacy and safety profile, it would be unethical to exclude patients receiving miglustat therapy from the study, given that the study itself will also be conducted at sites in Europe. However, it is planned to balance randomisation across the treatment groups for its use. The maximum dose proposed for this study is below the maximum dose for which long term clinical data is available in 2 patients (2800 mg/kg weekly for 3-5 years). Although individual clinicians have not always utilised an escalating rate of infusion, the reports of infusion related reactions in three patients suggest that this is an appropriate clinical strategy to mitigate the risk of such events and is consistent with dosing administration for other therapeutic agents. In the proposed study, treatment will be administered less frequently than has been undertaken in compassionate use. This longer dosing interval is supported by nonclinical data comparing the metabolism of cholesterol in non-human species with that in man; although a once weekly dosing interval was initially studied in man based on data in the mouse, HP-β-CD cholesterol metabolism/turnover in the mouse is 13-fold higher than in man which, in NPC-1, likely translates into a 13-fold slower accumulation of cholesterol in human cells compared with those of the mouse.Therefore, it is theorised that, given the slower cholesterol metabolism in humans, the dosing interval could be much less frequent in man than in mouse; however, based on what is known about cholesterol metabolism in humans and the pharmacokinetic and pharmacodynamic effect of HP-β-CD in the mouse, a dosing interval of 2 weeks in man is likely to be well within the therapeutic dosing interval and also minimises the amount of infusions required to be administered.
4 schema:endDate 2019-08-01T00:00:00Z
5 schema:keywords Attention
6 Biological Marker
7 C1
8 Completing
9 Europe
10 Evaluate
11 Evaluation Study as Topic
12 HP
13 Italy
14 NPC
15 Niemann-Pick disease
16 Organization and Administration
17 PD
18 Phase I/II
19 Spinal Puncture
20 Stage 1
21 Stage 2
22 Sweden
23 UK
24 accumulation
25 aphasia
26 approved treatment
27 assessment
28 ataxia
29 behavioral aspect
30 beta-cyclodextrin
31 blood
32 body
33 cell
34 cerebrospinal fluid
35 cholesterol
36 cholesterol metabolism
37 clinical data
38 clinical outcome
39 clinical strategy
40 condition
41 cyclo
42 cyclodextrins
43 defect
44 different dose
45 different dose level
46 doctor
47 dose level
48 dosing
49 drug
50 duration
51 early assessment
52 effectiveness
53 escalating
54 established efficacy
55 experimental treatment
56 first treatment
57 hearing
58 holding
59 human
60 human cell
61 individual
62 infusion
63 interval
64 intravenous infusion
65 laboratory experiment
66 liver biopsy
67 marker
68 maximum dose
69 metabolism
70 minimise
71 mouse
72 multi-centre
73 neurological function
74 non-human specie
75 organ damage
76 parallel group study
77 patient
78 patient use
79 pharmacodynamic effect
80 pharmacodynamics
81 phase I/II study
82 planned study
83 plasma pharmacokinetics
84 prevention
85 primary objective
86 protein
87 puncture
88 questionnaire
89 randomisation
90 recruitment
91 related reaction
92 research study
93 risk
94 saccade
95 safety
96 safety profile
97 sample
98 scientific literature
99 secondary objective
100 serum
101 stage
102 substance
103 therapeutic
104 therapeutic agent
105 therapy
106 translates
107 transport
108 treatment group
109 trial
110 urine sample
111 schema:name A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes
112 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02912793
113 schema:sdDatePublished 2019-03-07T15:26
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher N6d229ee3526d40968038f325b08b9965
116 schema:sponsor https://www.grid.ac/institutes/grid.412346.6
117 https://www.grid.ac/institutes/grid.415721.4
118 https://www.grid.ac/institutes/grid.83440.3b
119 schema:startDate 2017-03-01T00:00:00Z
120 schema:subjectOf sg:pub.10.1007/8904_2011_47
121 sg:pub.10.1007/s004399900059
122 sg:pub.10.1186/1750-1172-5-16
123 sg:pub.10.1186/s13023-015-0274-1
124 https://doi.org/10.1001/jama.282.12.1157
125 https://doi.org/10.1002/ajmg.b.30969
126 https://doi.org/10.1002/humu.10255
127 https://doi.org/10.1002/mds.10541
128 https://doi.org/10.1002/mds.21544
129 https://doi.org/10.1016/0022-3956(75)90026-6
130 https://doi.org/10.1016/j.fct.2005.03.007
131 https://doi.org/10.1016/j.ymgme.2012.03.012
132 https://doi.org/10.1016/s1474-4422(07)70194-1
133 https://doi.org/10.1073/pnas.0810895106
134 https://doi.org/10.1074/jbc.271.35.21604
135 https://doi.org/10.1086/302620
136 https://doi.org/10.1093/brain/awl260
137 https://doi.org/10.1097/aud.0b013e3182a362b8
138 https://doi.org/10.1126/science.290.5500.2298
139 https://doi.org/10.1126/scitranslmed.3010101
140 https://doi.org/10.1136/jnnp.2005.086785
141 https://doi.org/10.1172/jci72835
142 https://doi.org/10.1179/jmt.2009.17.3.163
143 https://doi.org/10.1194/jlr.m013789
144 https://doi.org/10.1194/jlr.m700525-jlr200
145 https://doi.org/10.1212/01.wnl.0000219042.60538.92
146 https://doi.org/10.1212/wnl.0b013e31828869f9
147 https://doi.org/10.1242/dmm.010124
148 https://doi.org/10.1371/journal.pone.0114669
149 schema:url https://clinicaltrials.gov/show/NCT02912793
150 sgo:license sg:explorer/license/
151 sgo:sdDataset clinical_trials
152 rdf:type schema:MedicalStudy
153 N6d229ee3526d40968038f325b08b9965 schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
156 rdf:type schema:DefinedTerm
157 anzsrc-for:3164 schema:inDefinedTermSet anzsrc-for:
158 rdf:type schema:DefinedTerm
159 sg:pub.10.1007/8904_2011_47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035654877
160 https://doi.org/10.1007/8904_2011_47
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s004399900059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047616516
163 https://doi.org/10.1007/s004399900059
164 rdf:type schema:CreativeWork
165 sg:pub.10.1186/1750-1172-5-16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005623887
166 https://doi.org/10.1186/1750-1172-5-16
167 rdf:type schema:CreativeWork
168 sg:pub.10.1186/s13023-015-0274-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005979361
169 https://doi.org/10.1186/s13023-015-0274-1
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1001/jama.282.12.1157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050564301
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1002/ajmg.b.30969 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026935211
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1002/humu.10255 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006616197
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1002/mds.10541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006635563
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1002/mds.21544 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053003540
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/0022-3956(75)90026-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027523106
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.fct.2005.03.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052037868
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/j.ymgme.2012.03.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027225530
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s1474-4422(07)70194-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021955671
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1073/pnas.0810895106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039042817
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1074/jbc.271.35.21604 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012367026
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1086/302620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058610189
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1093/brain/awl260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052588466
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1097/aud.0b013e3182a362b8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044245566
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1126/science.290.5500.2298 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062572556
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1126/scitranslmed.3010101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012551405
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1136/jnnp.2005.086785 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037485737
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1172/jci72835 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023308017
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1179/jmt.2009.17.3.163 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002816074
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1194/jlr.m013789 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014481242
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1194/jlr.m700525-jlr200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012167280
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1212/01.wnl.0000219042.60538.92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064348165
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1212/wnl.0b013e31828869f9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064357619
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1242/dmm.010124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019513430
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1371/journal.pone.0114669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037474842
220 rdf:type schema:CreativeWork
221 https://www.grid.ac/institutes/grid.412346.6 schema:Organization
222 https://www.grid.ac/institutes/grid.415721.4 schema:Organization
223 https://www.grid.ac/institutes/grid.83440.3b schema:Organization
 




Preview window. Press ESC to close (or click here)


...